EUCTR2021-001404-14-ES进行中（未招募）1 期
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension. - REFRESH
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able to understand and willing to provide written informed consent, and able to comply with the study procedures and restrictions.
- •2. Adult men and women (at Screening).
- •3. Diagnosis of primary HTN for at least 6 months prior to Screening and:
- •Currently treated with 2 antihypertensive classes of drug (difficult-to-treat subjects), or currently treated with at least 3 antihypertensive classes of drug including a diuretic (treatment resistant subjects), at the MTDs of those medications (ie, the subject can tolerate the current dose of each medication but higher doses have caused or may worsen side effects), with no change in their antihypertensive regimen (drug, dose, or schedule) for at least 6 weeks, and with medication adherence =80% during the Run in Period.
- •Have a systolic AOBP between 140 mmHg and 179 mmHg (inclusive) at Screening while on their current chronic antihypertensive treatments.
- •Have a successful ABPM measurement with a mean systolic daytime ABP >135 mmHg after the Run-in Period while on their current chronic antihypertensive treatments. An ABPM is successful if at least 21 daytime readings and 6 nighttime readings have been successfully recorded.
- •4. Women of childbearing potential and nonsurgically sterile male subjects who are sexually active must agree to use an approved highly effective form of contraception from the time of informed consent until 30 days post dose. Approved forms of contraception include hormonal intrauterine devices, hormonal contraceptives (oral birth control pills, depo, patch, or injectable) together with supplementary barrier methods such as condoms or diaphragms with spermicidal gel or foam.
- •5. Women of childbearing potential must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test result at the Inclusion Visit (Visit 2B, Day 1).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 500
排除标准
- •1. Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN, pheochromocytoma, Cushing’s disease).
- •2. Systolic AOBP =180 mmHg or DBP =110 mmHg at the Screening or Inclusion Visit (Visit 2B, Day 1) and confirmed by a second measurement within 30 minutes to 1 hour.
- •3. Known hypertensive retinopathy (Keith-Wagener Grade 3 or Grade 4) and/or hypertensive encephalopathy.
- •4. Upper arm circumference that is outside the limits of the study-provided BP cuff associated with either the ABPM and/or AOBP measurement device.
- •5. History of spontaneous or drug-induced angioedema.
- •6. History of any drug-related allergy or hypersensitivity to any components of the IP (firibastat [QGC001] or placebo).
- •7. Known severe aortic stenosis (symptomatic or asymptomatic with valvular indexed surface <0.5 cm²/m²).
- •8. Subjects with severe symptomatic heart failure (New York Heart Association [NYHA] Class III or Class IV).
- •9. History of acute coronary syndrome (non-ST elevation myocardial infarction [MI], ST elevation MI, and unstable angina pectoris), stroke, or transient ischemic attack within 6 months prior to Visit 2A, Day 0.
- •10. Known history of malabsorption syndrome, or has undergone gastrointestinal surgery, including bariatric procedures that induce chronic malabsorption, within 2 years of Screening.
- •11. Treatment with anti-obesity drugs or procedures 3 months prior to Screening (ie, surgery, aggressive diet regimen, etc.), leading to unstable body weight.
- •12. Female who is breastfeeding, pregnant, or planning to become pregnant during the study period.
- •13. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 3 years.
- •14. Shift workers who routinely sleep during the daytime and/or whose work hours include midnight.
- •15. Subjects with moderate to severe hepatic impairment (Child-Pugh A, B, or C); alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >3×upper limit of normal (ULN), or a total bilirubin =1.5×ULN (unless secondary to Gilbert’s syndrome), or direct bilirubin >ULN in subjects with Gilbert’s syndrome at Screening.
- •16. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Levey AS, et al. 2009) at Screening.
- •17. History of any blood disorder, other than sickle cell trait, causing hemolysis or unstable red blood cells (eg, malaria, babesiosis, hemolytic anemia, thalassemia, sickle cell anemia).
- •18. Subjects with documented DI.
- •19. Subjects with Type 1 diabetes mellitus.
- •20. Subjects with Type 2 diabetes mellitus who:
- •Are poorly controlled, defined as glycosylated hemoglobin A1c (HbA1c) >9% at Screening; OR
- •Are taking short-acting insulin. Use of a stable dose [=12 weeks prior to Screening] of the following medications, (or any combination of the following medications) is permitted: glucagon like peptide 1 analog, metformin, sulfonylurea, dipeptidyl peptidase-4 inhibitor, and single basal insulin, sodium glucose co-transporter 2 (SGLT2) inhibitors and pioglitazone.
- •21. Routine or anticipated treatment with any systemic corticosteroid. Use of topical, inhaled, intra articular or nasal corticosteroids is permitted.
- •22. Clinical evidence of thyroid disease, thyroid hormone therapy that is not stable =4 weeks prior to Screening, or a thyroid-stimulating hormone (TSH) level <0.75×lower limit of normal or >1.5×ULN at Screening.
- •23. History of
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy (RT/CT)EUCTR2004-002016-28-ITAMGE
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2010-022760-12-ITJanssen-Cilag International N.V.1,281
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate theEfficacy and Safety of Weekly Doses of Palifermin (Recombinant HumanKeratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis inSubjects With Advanced Head and Neck Cancer Receiving Radiotherapy WithConcurrent Chemotherapy (RT/CT). - Palifermin 2002402EUCTR2005-000213-35-ITAMGEN S.P.A.180
进行中（未招募）
1 期
An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Disease Type Ia.EUCTR2020-004184-12-PTltragenyx Pharmaceutical Inc.50
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD TherapyMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2019-002021-29-ESGilead Sciences Inc.390